Orris

Make a introduction aims objective for irb of title “A STUDY OF CORRELATION BETWEEN BODY MASS INDEX WAIST HIP RATIO AND LIPID PROFILE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Reading Document
Medical Text Search

BMI waist hip ratio lipid profile type 2 diabetes mellitus correlation

Medical Text Search

obesity anthropometric measures dyslipidemia insulin resistance type 2 diabetes

GradeResponse
GradeResponse
Here is a fully written Introduction, Aims, and Objectives for your IRB submission:

INSTITUTIONAL REVIEW BOARD (IRB) SUBMISSION

Title: A Study of Correlation Between Body Mass Index, Waist-Hip Ratio, and Lipid Profile in Patients with Type 2 Diabetes Mellitus

I. INTRODUCTION

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by progressive insulin resistance and relative insulin deficiency, resulting in persistent hyperglycemia. It represents one of the most significant global public health burdens of the 21st century, with prevalence rising sharply in parallel with increasing rates of obesity and sedentary lifestyles.
Obesity and adiposity play a central role in the pathophysiology of T2DM. Expansion of adipocyte mass accompanied by decreased insulin sensitivity has multiple adverse effects on lipid metabolism. Increased free fatty acid delivery from insulin-resistant adipose tissue to the liver promotes excessive hepatic VLDL (Very Low-Density Lipoprotein) production, elevated triglycerides, and reduced HDL-cholesterol — a constellation commonly termed diabetic dyslipidemia. Dyslipidemia in T2DM patients is a well-recognized independent risk factor for atherosclerotic cardiovascular disease (ASCVD), the leading cause of morbidity and mortality in this population (Harrison's Principles of Internal Medicine, 21st Edition, p. 11449).
Anthropometric indices such as Body Mass Index (BMI) and Waist-Hip Ratio (WHR) are widely used clinical tools for assessing overall adiposity and central obesity, respectively. While BMI reflects total body fat, WHR more specifically captures the pattern of fat distribution, particularly visceral adiposity, which is more metabolically detrimental. Prospective observational studies have demonstrated that waist circumference and waist-to-hip ratio are superior predictors of ASCVD risk and T2DM complications compared to weight or BMI alone, though these measures are considered complementary rather than mutually exclusive (Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk, p. 10).
Despite the established biological link between central obesity and dyslipidemia in T2DM, quantitative correlations between BMI, WHR, and individual lipid parameters — including Total Cholesterol (TC), Triglycerides (TG), LDL-cholesterol, HDL-cholesterol, and VLDL — remain understudied in the local patient population. Understanding these correlations may help clinicians identify high-risk diabetic patients earlier, guide lifestyle interventions, and prioritize lipid-lowering therapy.

II. AIMS

  1. To study the correlation between Body Mass Index (BMI) and lipid profile parameters in patients with Type 2 Diabetes Mellitus.
  2. To study the correlation between Waist-Hip Ratio (WHR) and lipid profile parameters in patients with Type 2 Diabetes Mellitus.
  3. To compare the utility of BMI versus WHR as predictors of dyslipidemia in T2DM.

III. OBJECTIVES

Primary Objectives

  1. To measure and analyze BMI and Waist-Hip Ratio in enrolled patients with confirmed Type 2 Diabetes Mellitus.
  2. To assess the fasting lipid profile (Total Cholesterol, Triglycerides, LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol) in all enrolled participants.
  3. To determine the statistical correlation between BMI and each lipid parameter (TC, TG, LDL, HDL, VLDL) in T2DM patients.
  4. To determine the statistical correlation between Waist-Hip Ratio and each lipid parameter (TC, TG, LDL, HDL, VLDL) in T2DM patients.

Secondary Objectives

  1. To evaluate the prevalence of dyslipidemia among T2DM patients categorized by BMI class (normal, overweight, obese).
  2. To evaluate the prevalence of dyslipidemia among T2DM patients stratified by WHR (normal vs. high WHR).
  3. To compare the strength of correlation between BMI vs. WHR with lipid parameters to identify the more clinically predictive anthropometric measure.
  4. To assess the association of demographic variables (age, sex, duration of diabetes, glycemic control) with lipid profile abnormalities in the study population.

IV. HYPOTHESES

  • Null Hypothesis (H₀): There is no significant correlation between BMI/Waist-Hip Ratio and lipid profile parameters in patients with Type 2 Diabetes Mellitus.
  • Alternate Hypothesis (H₁): There is a significant positive correlation between BMI/Waist-Hip Ratio and atherogenic lipid parameters (TC, TG, LDL, VLDL), and a significant negative correlation with HDL-cholesterol, in patients with Type 2 Diabetes Mellitus.
Note for submission: Ensure that the study protocol includes standardized procedures for anthropometric measurements (BMI per WHO criteria; WHR using a non-elastic tape at the umbilical level for waist and maximum gluteal circumference for hip), and that lipid profile analysis is performed on fasting venous blood samples using standard enzymatic assays in an accredited laboratory.

Methodology study design duration center population inclusion exclusion sample size data collection and analysis

Medical Text Search

BMI waist hip ratio lipid profile type 2 diabetes mellitus study methodology

Medical Text Search

type 2 diabetes mellitus diagnostic criteria inclusion exclusion clinical study

GradeResponse
GradeResponse
Here is the complete Methodology section for your IRB submission:

V. METHODOLOGY

1. STUDY DESIGN

This will be a hospital-based, cross-sectional observational study designed to assess the correlation between anthropometric indices (Body Mass Index and Waist-Hip Ratio) and fasting lipid profile parameters in patients with confirmed Type 2 Diabetes Mellitus.
A cross-sectional design is appropriate as it allows simultaneous measurement of exposure variables (BMI, WHR) and outcome variables (lipid parameters) at a single point in time, enabling correlation analysis across a defined patient population without follow-up burden.

2. STUDY DURATION

  • Total study duration: 18 months
    • Ethical clearance and preparation: 1 month
    • Patient enrollment and data collection: 12 months
    • Data entry, analysis, and write-up: 5 months

3. STUDY CENTER

  • Setting: Department of General Medicine / Endocrinology / Diabetology, [Name of Hospital/Medical College]
  • Type of center: Tertiary care teaching hospital
  • Patients will be recruited from the outpatient department (OPD) and inpatient wards of the respective department.

4. STUDY POPULATION

The study population will consist of adult patients diagnosed with Type 2 Diabetes Mellitus attending the OPD or admitted to the wards of the study center during the study period.
Diagnosis of T2DM will be confirmed by standard ADA/WHO criteria, including any one of the following:
  • Fasting plasma glucose ≥ 126 mg/dL on two occasions
  • 2-hour plasma glucose ≥ 200 mg/dL during a 75g OGTT
  • HbA1c ≥ 6.5%
  • Random plasma glucose ≥ 200 mg/dL with classic symptoms of hyperglycemia
(Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus, p. 1)

5. INCLUSION CRITERIA

  1. Patients aged 18 to 70 years of either sex
  2. Previously diagnosed or newly diagnosed Type 2 Diabetes Mellitus (by ADA/WHO criteria)
  3. Patients willing to give written informed consent
  4. Patients able to undergo anthropometric measurements and fasting blood sample collection
  5. Patients on oral antidiabetic agents (with or without insulin)

6. EXCLUSION CRITERIA

  1. Type 1 Diabetes Mellitus, Gestational Diabetes, or secondary diabetes (drug-induced, pancreatogenic)
  2. Patients currently on lipid-lowering drugs (statins, fibrates, niacin) that would independently alter the lipid profile
  3. Known cases of hypothyroidism, Cushing's syndrome, or other endocrinopathies that affect lipid or glucose metabolism
  4. Patients with chronic kidney disease (CKD stage 3–5), hepatic disease, or nephrotic syndrome
  5. Patients with acute infections, febrile illness, or any acute metabolic decompensation at the time of enrollment
  6. Pregnancy or lactation
  7. Patients with physical deformities that prevent accurate anthropometric measurements (e.g., limb amputations, severe scoliosis)
  8. Patients who have consumed alcohol within 48 hours prior to blood sampling
  9. Patients unwilling to participate or unable to provide informed consent

7. SAMPLE SIZE

Sample size calculation is based on a prior study reporting a correlation coefficient (r) of 0.35 between WHR and triglyceride levels in T2DM patients.
Using the formula:
$$n = \frac{(Z_{\alpha/2} + Z_\beta)^2}{(0.5 \cdot \ln\frac{1+r}{1-r})^2} + 3$$
Where:
  • Z α/2 = 1.96 (at 95% confidence interval, α = 0.05)
  • Z β = 0.842 (at 80% power)
  • r = 0.35 (expected correlation coefficient)
Calculated sample size = approximately 95–100 patients
Accounting for a 10% dropout or incomplete data rate, a final sample of 110 patients will be enrolled.

8. DATA COLLECTION

A. Demographic and Clinical Data

A pre-designed, structured proforma/case record form (CRF) will be used to collect:
  • Age, sex, occupation, socioeconomic status
  • Duration of diabetes
  • Current antidiabetic medications and comorbidities
  • Blood pressure, smoking/alcohol history
  • Family history of diabetes and cardiovascular disease

B. Anthropometric Measurements

ParameterMethod
WeightDigital weighing scale, light clothing, no footwear (nearest 0.1 kg)
HeightStadiometer in standing position (nearest 0.1 cm)
BMIWeight (kg) / Height² (m²); classified per WHO criteria
Waist CircumferenceNon-elastic tape at the midpoint between lower costal margin and iliac crest, at end of normal expiration
Hip CircumferenceMaximum circumference over the buttocks at the level of greater trochanters
Waist-Hip Ratio (WHR)Waist (cm) ÷ Hip (cm); elevated if >0.90 in males, >0.85 in females (WHO cutoffs)
BMI Classification (WHO):
BMI (kg/m²)Category
< 18.5Underweight
18.5 – 24.9Normal
25.0 – 29.9Overweight
≥ 30.0Obese
(Overweight and Obesity Management, p. 139)

C. Biochemical Investigations

All blood samples will be collected in the fasting state (10–12 hours overnight fast) via venipuncture and processed in an accredited biochemistry laboratory.
Fasting Lipid Profile:
ParameterReference Range
Total Cholesterol (TC)< 200 mg/dL (desirable)
Triglycerides (TG)< 150 mg/dL
LDL-Cholesterol< 100 mg/dL (in diabetics)
HDL-Cholesterol≥ 40 mg/dL (males), ≥ 50 mg/dL (females)
VLDL-Cholesterol2–30 mg/dL
Additional parameters:
  • Fasting plasma glucose (FPG)
  • HbA1c
  • Serum creatinine and urine albumin-creatinine ratio (to screen for renal exclusions)
  • Thyroid function tests (TSH) — if clinically indicated for exclusion

9. DATA ANALYSIS

All data will be entered and analyzed using SPSS version 25.0 (or equivalent statistical software such as R or STATA).

A. Descriptive Statistics

  • Continuous variables (age, BMI, WHR, lipid values): expressed as Mean ± Standard Deviation (SD)
  • Categorical variables (sex, BMI category, WHR category): expressed as frequency and percentage (%)

B. Normality Testing

  • Shapiro-Wilk test or Kolmogorov-Smirnov test will be applied to all continuous variables to determine distribution.

C. Correlation Analysis

  • Pearson's correlation coefficient (r) will be used for normally distributed variables.
  • Spearman's rank correlation (ρ) will be applied for non-normally distributed data.
  • Correlation will be performed between:
    • BMI vs. TC, TG, LDL, HDL, VLDL
    • WHR vs. TC, TG, LDL, HDL, VLDL

D. Comparative Analysis

  • Independent t-test or Mann-Whitney U test (based on distribution) will compare lipid parameters between normal and elevated BMI/WHR groups.
  • One-way ANOVA with post-hoc Tukey test will compare lipid parameters across BMI categories (normal, overweight, obese).

E. Multivariate Analysis

  • Multiple linear regression will be performed to identify independent predictors of dyslipidemia after adjusting for confounders (age, sex, duration of diabetes, HbA1c, blood pressure).

F. Level of Significance

  • A p-value < 0.05 will be considered statistically significant for all analyses.

10. ETHICAL CONSIDERATIONS

  • Written informed consent will be obtained from all participants prior to enrollment.
  • The study will be conducted in accordance with the Declaration of Helsinki (revised 2013) and ICH-GCP guidelines.
  • Confidentiality of patient data will be maintained; all records will be anonymized using coded identifiers.
  • No additional invasive procedures beyond routine clinical investigations will be performed.
  • The study carries minimal risk to participants; there will be no withholding of standard medical care.
  • IRB/IEC approval will be obtained before commencement of data collection.
Proforma, informed consent form, and patient information sheet should be attached as annexures to the IRB submission.
This is a shared conversation. Sign in to Orris to start your own chat.